Literature DB >> 24303494

Hypoglycemia associated with fluoxetine treatment in a patient with type 1 diabetes.

Betina Biagetti1, Rosa Corcoy.   

Abstract

We report on a patient with type 1 diabetes mellitus who presented with recurrent episodes of hypoglycemia and a marked reduction in her daily insulin requirements after introduction of fluoxetine. This 25-year-old Caucasian woman had been followed up at the outpatient clinic for type 1 diabetes mellitus and pre-pregnancy care. She used a continuous subcutaneous insulin infusion with lispro and her daily insulin dose was 0.5 IU/kg per day. She had no chronic diabetic complications or hypoglycemia unawareness. Fluoxetine at a daily dose of 20 mg had been started because of depressive symptoms and within one week, she presented recurrent hypoglycemic episodes that prompted a progressive reduction in the insulin dose down to 0.3 IU/kg per day. The reduced insulin requirements continued during the period of fluoxetine treatment while glycated hemoglobin remained stable. She had no concurrent additional cause to explain the reduced insulin requirements. After fluoxetine was stopped, insulin requirements progressively increased and returned to the patient´s usual dose.

Entities:  

Keywords:  Diabetes mellitus; Fluoxetine; Hypoglycemia; Selective serotonin-reuptake inhibitor

Year:  2013        PMID: 24303494      PMCID: PMC3845947          DOI: 10.12998/wjcc.v1.i5.169

Source DB:  PubMed          Journal:  World J Clin Cases        ISSN: 2307-8960            Impact factor:   1.337


  20 in total

1.  Loss of hypoglycemia awareness in an adolescent with type 1 diabetes mellitus during treatment with fluoxetine hydrochloride.

Authors:  A M Sawka; V Burgart; D Zimmerman
Journal:  J Pediatr       Date:  2000-03       Impact factor: 4.406

2.  Association between CYP2C9 slow metabolizer genotypes and severe hypoglycaemia on medication with sulphonylurea hypoglycaemic agents.

Authors:  A Holstein; A Plaschke; M Ptak; E-H Egberts; J El-Din; J Brockmöller; J Kirchheiner
Journal:  Br J Clin Pharmacol       Date:  2005-07       Impact factor: 4.335

3.  Fluoxetine improves insulin sensitivity in obese patients with non-insulin-dependent diabetes mellitus independently of weight loss.

Authors:  P Maheux; F Ducros; J Bourque; J Garon; J L Chiasson
Journal:  Int J Obes Relat Metab Disord       Date:  1997-02

4.  Effect of some antidepressants on glycaemia and insulin levels of normoglycaemic and alloxan-induced hyperglycaemic mice.

Authors:  A Erenmemisoglu; U K Ozdogan; R Saraymen; A Tutus
Journal:  J Pharm Pharmacol       Date:  1999-06       Impact factor: 3.765

5.  [Suggestive episodes of hypoglycemia related to fluoxetine].

Authors:  M I Fernández López; J Sánchez Esteban; J Jímenez Belló; A Meseguer Zaragoza
Journal:  Aten Primaria       Date:  1996-12       Impact factor: 1.137

Review 6.  Drug interactions with oral antidiabetic agents: pharmacokinetic mechanisms and clinical implications.

Authors:  Aleksi Tornio; Mikko Niemi; Pertti J Neuvonen; Janne T Backman
Journal:  Trends Pharmacol Sci       Date:  2012-04-02       Impact factor: 14.819

Review 7.  Glucose dysregulation associated with antidepressant agents: an analysis of 17 published case reports.

Authors:  Star Khoza; Jamie C Barner
Journal:  Int J Clin Pharm       Date:  2011-04-13

8.  Fluoxetine increases insulin action in obese type II (non-insulin dependent) diabetic patients.

Authors:  B J Potter van Loon; J K Radder; M Frölich; H M Krans; A H Zwinderman; A E Meinders
Journal:  Int J Obes Relat Metab Disord       Date:  1992-12

Review 9.  Depression in adults with diabetes.

Authors:  P J Lustman; L S Griffith; J A Gavard; R E Clouse
Journal:  Diabetes Care       Date:  1992-11       Impact factor: 19.112

10.  Increased mortality of patients with diabetes reporting severe hypoglycemia.

Authors:  Rozalina G McCoy; Holly K Van Houten; Jeanette Y Ziegenfuss; Nilay D Shah; Robert A Wermers; Steven A Smith
Journal:  Diabetes Care       Date:  2012-06-14       Impact factor: 19.112

View more
  5 in total

1.  Human Beta Cells Produce and Release Serotonin to Inhibit Glucagon Secretion from Alpha Cells.

Authors:  Joana Almaça; Judith Molina; Danusa Menegaz; Alexey N Pronin; Alejandro Tamayo; Vladlen Slepak; Per-Olof Berggren; Alejandro Caicedo
Journal:  Cell Rep       Date:  2016-12-20       Impact factor: 9.423

2.  Targeting the Pancreatic α-Cell to Prevent Hypoglycemia in Type 1 Diabetes.

Authors:  Julia K Panzer; Alejandro Caicedo
Journal:  Diabetes       Date:  2021-12       Impact factor: 9.461

3.  The antidepressant-like activity of AC-5216, a ligand for 18KDa translocator protein (TSPO), in an animal model of diabetes mellitus.

Authors:  Zhi-Kun Qiu; Jia-Li He; Xu Liu; Guan-Hua Zhang; Jia Zeng; Hong Nie; Yong-Gang Shen; Ji-Sheng Chen
Journal:  Sci Rep       Date:  2016-11-25       Impact factor: 4.379

4.  The Influence of CYP2D6 and CYP2C19 Genetic Variation on Diabetes Mellitus Risk in People Taking Antidepressants and Antipsychotics.

Authors:  Isabelle Austin-Zimmerman; Marta Wronska; Baihan Wang; Haritz Irizar; Johan H Thygesen; Anjali Bhat; Spiros Denaxas; Ghazaleh Fatemifar; Chris Finan; Jasmine Harju-Seppänen; Olga Giannakopoulou; Karoline Kuchenbaecker; Eirini Zartaloudi; Andrew McQuillin; Elvira Bramon
Journal:  Genes (Basel)       Date:  2021-11-03       Impact factor: 4.096

5.  The selective serotonin reuptake inhibitor fluoxetine has direct effects on beta cells, promoting insulin secretion and increasing beta-cell mass.

Authors:  Bo Liu; Inmaculada Ruz-Maldonado; Klaudia Toczyska; Oladapo E Olaniru; Mohammed Gulrez Zariwala; David Hopkins; Min Zhao; Shanta J Persaud
Journal:  Diabetes Obes Metab       Date:  2022-07-11       Impact factor: 6.408

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.